Wells Fargo maintains Fate Therapeutics at Equal-Weight, lowers price target to $3 from $3.50

Wells Fargo kept Fate Therapeutics at Equal-Weight but cut its price target to $3 from $3.50, a 14.3% reduction. This implies a 62.2% upside from the Nov 5 close of $1.85, according to the bank.

Original reporting
Published Nov 6, 2026, 2:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 2:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Wells Fargo maintains Fate Therapeutics at Equal-Weight, lowers price target to $3 from $3.50 — source image
Decision brief

The 30-second read

$FATEBearishMed
01

Why it matters

The downgrade may trigger short‑term selling pressure but does not change the underlying Equal‑Weight stance.

02

Market read

Analyst target reduction is a modest catalyst for a small‑cap biotech, offering a short‑term trading edge.

03

What to watch

Recent clinical trial updates not mentioned may offset the downgrade.

Relevance 6/10Novelty 6/10Timing: today

Background

Wells Fargo maintains an Equal‑Weight rating on Fate Therapeutics while adjusting its price target.

Company-level read

Ticker impact

$FATEBearishMedium confidence
Context

Wells Fargo lowered its price target on Fate Therapeutics to $3 from $3.50, indicating a 14.3% reduction.

Expected impact

likely downside as the market prices in the lower target

Evidence & confidence

Analyst downgrade typically leads to short-term price weakness, especially for a small‑cap biotech.

Market effects

May weigh on other small‑cap biotech stocks as analysts tighten targets.

Limited to U.S. biotech sector.

Low

Counterpoint

Target cut could be an overreaction; upside potential remains if upcoming trial data exceeds expectations.

Key entities

  • Wells Fargo

    Provides research coverage and price target for Fate Therapeutics.

  • Fate Therapeutics

    Biotech firm listed on Nasdaq (FATE).

Related articles

$FATEHigh

Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

FATE THERAPEUTICS INC (FATE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates Safety profile presented at ASN Kidney Week 2026 across 29 autoimmune patients treated with a single dose of FT819 and fludarabine-free, less-intensive conditioning continues to be fa

$FATEMed

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

FATE THERAPEUTICS INC (FATE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN $15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Thera

$FATEMedAI 8/10

Fate Therapeutics, Inc.: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

Fate Therapeutics (NASDAQ: FATE) dosed the first patient in its Phase 2 potentially registrational RECLAIM-LN trial of FT819 for refractory moderate-to-severe SLE with Class III or IV lupus nephritis. The single-arm study targets about 53 patients, with complete renal response at Week 26 as the primary endpoint. Enrollment is expected to finish in 15-18 months, by 1H2028.

$FATEMed

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

FATE THERAPEUTICS INC (FATE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated